In a recent study, talk therapy in Parkinson’s disease led to significant improvement in patients' well-being, ...

Researchers at Karolinska Institutet have discovered new insights into brain changes in Parkinson's disease using advanced ...

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.

Danish film director Lars von Trier has been admitted to a care facility for Parkinson’s disease, his producer said Wednesday ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

Conductor Daniel Barenboim says he has been diagnosed with Parkinson’s disease. The 82-year-old issued a statement Thursday ...

Ozzy Osbourne will come out of touring retirement and reunite with the full Black Sabbath lineup for the first time in 20 ...

By creating a new metric, researchers envision the possibility of diagnostic and treatment advances for the disease, which is estimated to affect about 4 million people worldwide.

From a study that analyzed brain images of more than 2,500 people with Parkinson's disease in 20 different countries, scientists were able to identify patterns of neurodegeneration and create metrics ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...